The China-based property and land developer will aim to bring technology developed by US firms through the incubator to the Chinese market.

This is promising for other groups, such as Canada and South Africa-based energy groups Cenovus and Sasol, which have decided against continuing or forming a formal corporate venturing programme, senior executives at both companies said.

US molecular biology specialist Qiagen has co-led a $27m series B round of funding for Exosome Diagnostics, a US developer of fluid-based molecular diagnostics.

The kidney disease treatment developer, which has secured funding from Novartis and Novo, has raised $106.9m after underwriters took up the option to buy additional shares.

Telus Health, the healthcare arm of Canadian mobile operator Telus, has made a strategic investment worth $3m in PatientSafe Solutions, a producer of mobile hospital workflow systems.

NephroGenex has closed an initial public offering of 3.1 million shares of common stock.

US-based Genocea Biosciences has raised an approximate net value of $61.4m from selling 5.5 millions shares of common stock at a price of $12 per share in an initial public offering.

US-based biopharmaceutical company Dicerna Pharmaceuticals has closed their initial public offering selling 6.9 million shares of common stock.

Molecular oncology diagnostics company Biocept has raised $19m in their initial public offering by selling 1.9 million shares of common stock.